Verrica Pharmaceuticals Inc. VRCA
4.37
0.01
0.23%
as of 25 Sep
- Market cap
- $74.9M
- P/E
- 0.0×
Follow VRCA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 473.29% | 1,414.20% | (240.35%) | 101.83% |
+8 more TTM periods Free account |
|
| (83.02%) | (44.03%) | (35.33%) | (70.48%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(300.59%) | (98.48%) | (67.98%) | (342.65%) | |
Average Days of Receivables |
133.50 | 76.74 | 55.37 | 86.77 | |
Free Cash Flow per Share |
(0.63) | (0.66) | (1.65) | (3.07) | |
Free Cash Flow |
(13.35) | (14.11) | (17.63) | (29.10) | |
Piotroski F-Score |
5.00 | 6.00 | 6.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(81.89%) | (37.94%) | (31.74%) | (75.07%) | |
Accounts Receivable Turnover |
2.13 | 5.52 | 13.00 | 8.32 | |
Accounts Payable Turnover |
2.18 | 2.14 | 1.73 | 2.09 | |
Inventory Turnover |
1.63 | 1.76 | 1.46 | 1.09 | |
Average Days of Payables |
136.80 | 205.61 | 219.78 | 217.08 | |
Days of Inventory on Hand |
231.44 | 185.08 | 237.18 | 315.56 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
48.21% | 28.07% | 24.89% | 24.34% | |
Selling, General and Administrative Expense of Revenue |
124.86% | 97.85% | 99.00% | 119.96% | |
Share Based Compensation of Revenue |
11.59% | 8.58% | 9.33% | 10.99% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.43 | 0.79 | 0.99 | 1.12 | |
Depreciation/Fixed assets |
4.38 | 4.02 | 3.74 | 3.75 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.42 | 1.74 | 3.34 | 3.25 | |
Operating CF per Share |
(0.63) | (0.66) | (1.65) | (3.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(102.84%) | (47.97%) | (50.27%) | (84.38%) |
Columns are period end dates